JAK / Stat
-
XL019
Catalog No. A12394 -
Pyridone 6 (JAK Inhibitor I)
Catalog No. A13457 -
TG-02 (SB1317)
Catalog No. A11962 -
Cerdulatinib
Catalog No. A14210 multi-targeted tyrosine kinase 抑制剂Cerdulatinib (PRT-062070)是多靶点酪氨酸激酶抑制剂,对JAK1/JAK2/JAK3/TYK2和Syk的IC50分别为12 nM/6 nM/8 nM/0.5 nM和32 nM。 了解更多 -
Baricitinib phosphate
Catalog No. A15014 JAK 抑制剂Baricitinib phosphate是一种选择性的JAK1和JAK2抑制剂,IC50为5.9 nM和5.7 nM,选择性是JAK3和Tyk2的?70和?10倍,对c-Met和Chk2没有抑制作用。 了解更多 -
CHZ868
Catalog No. A15937 -
SB1317 (TG02)
Catalog No. A13454 CDK/JAK2/FLT3 抑制剂SB1317是细胞周期蛋白依赖性激酶(CDKs)、类FMS酪氨酸激酶-3(FLT3)和Janus激酶2(JAK2)的有效抑制剂,CDK2、JAK2和FLT3的IC50值分别为13nM、56nM和73nM。 了解更多 -
PF-06651600
Catalog No. A16803 JAK3 抑制剂PF-06651600是一种有效且不可逆的JAK3选择性抑制剂,IC50为33.1 nM,但对JAK1,JAK2和TYK2没有活性(IC50> 10 000 nM)。 了解更多 -
Ruxolitinib Phosphate
Catalog No. A11552 JAK 抑制剂Ruxolitinib Phosphate是ruxolitinib的磷酸盐形式,ruxolitinib是一种口服生物可利用的Janus相关激酶(JAK)抑制剂,具有潜在的抗肿瘤和免疫调节活性。 了解更多 -
PF-06700841 tosylate
Catalog No. A17176 -
JAK3-IN-2
Catalog No. A18323 JAK3 抑制剂JAK3-IN-2 is a potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM. dispalys >4,300-fold selectivity over JAK1, JAK2 and TYK2, and other kinases BMX, EGFR, ITK and BTK; blocks cytokine signaling through JAK3, but not through other JAK family enzymes; inhibits IL-7 induced pSTAT5 in CD3+, CD8+ T cells with IC50 of 280 nM; sufficiently blocks the development of inflammation in a rat model of rheumatoid arthritis, while sparing hematopoiesis. 了解更多 -
Abrocitinib (PF-04965842)
Catalog No. A18318 JAK1 抑制剂Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease. 了解更多 -
Upadacitinib (ABT-494)
Catalog No. A18316 JAK-1 抑制剂Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. IC50 & Target: IC50: 43 nM (JAK1), 200 nM (JAK2) 了解更多 -
BMS-986165
Catalog No. A18726 TYK2 抑制剂BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2. BMS-986165 Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease. 了解更多 -
JAK3 covalent inhibitor-1
Catalog No. A18926 JAK3 covalent 抑制剂JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. 了解更多 -
Tofacitinib
Catalog No. A17252 JAK3/2/1 inhibitorTofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. 了解更多 -
PF-06263276
Catalog No. A12572 pan-JAK inhibitorPF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. 了解更多 -
Ruxolitinib sulfate
Catalog No. A11467 JAK1/2 inhibitorRuxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. 了解更多 -
JAK/HDAC-IN-1
Catalog No. A13362 JAK2/HDAC dual inhibitorJAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. 了解更多 -
Oclacitinib maleate
Catalog No. A16640 JAK inhibitorOclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM). 了解更多 -
NVP-BSK805 dihydrochloride
Catalog No. A21406 JAK2 inhibitorNVP-BSK805 dihydrochloride (BSK805 dihydrochloride) is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. 了解更多 -
PF-06700841 P-Tosylate
Catalog No. A21652 dual JAK1/TYK2 inhibitorPF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. 了解更多 -
Momelotinib Mesylate
Catalog No. A21658 JAK1/JAK2 inhibitorMomelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. 了解更多 -
Nitidine chloride
Catalog No. A14701 -
Corylifol A
Catalog No. A15729 -
Nifuroxazide
Catalog No. A16220 -
S3I-201 (NSC 74859)
Catalog No. A10817 Stat3 抑制剂S3I-201(NSC 74859)是Stat3的新型抑制剂,可在体外抑制Stat3,Stat3复合物的形成以及Stat3-DNA结合活性(IC50 = 86±33 ?M)和Stat3依赖性转录活性。 了解更多 -
Artesunate
Catalog No. A10087 cytochrome oxidase 抑制剂Artesunate是用于治疗疟疾的青蒿素的半合成衍生物。它也被证明可以有效对抗其他寄生虫,例如肝吸虫。青蒿琥酯还显示出针对不同肿瘤类型的癌细胞系的细胞毒性作用。青蒿琥酯已显示出通过抑制类风湿关节炎成纤维细胞样滑膜细胞中的NF-B和PI3激酶/ Akt信号通路来抑制TNF诱导的促炎细胞因子的产生。 了解更多 -
Cryptotanshinone
Catalog No. A10244 Stat3 抑制剂Cryptotanshinone是一种STAT3抑制剂,在DU145细胞中能显着阻断STAT3 Tyr705磷酸化,但不能阻断STAT3 Ser727磷酸化,并显着抑制JAK2磷酸化,IC50为?5μM,而不影响上游激酶c的磷酸化。 了解更多 -
Fludarabine Phosphate (Fludara)
Catalog No. A10395 Fludarabine Phosphate (Fludara)是一种用于治疗血液恶性肿瘤(血细胞癌,如白血病和淋巴瘤)的化疗药物。氟达拉滨通过干扰核糖核苷酸还原酶和dna聚合酶来抑制DNA合成。它对分裂细胞和静止细胞都有活性。 了解更多 -
Fludarabine (Fludara)
Catalog No. A10396 STAT 抑制剂Fludarabine或fludarabine(fludara)是一种用于治疗血液恶性肿瘤(血细胞癌,如白血病和淋巴瘤)的化疗药物。Fludarabine通过干扰核糖核苷酸还原酶和DNA聚合酶来抑制DNA合成。它对分裂细胞和静止细胞都有活性。 了解更多 -
SH-4-54
Catalog No. A14249 -
STAT5 Inhibitor
Catalog No. A13628 STAT 抑制剂STAT5抑制剂是一种细胞可渗透的非肽烟酰yl,可通过靶向其SH2结构域(针对STAT5βSH2结构域EPO肽结合活性的IC50 = 47μM)来抑制STAT5。 了解更多